DOMA Perpetual Director Nominees Send Letter to Shareholders of Pacira Biosciences
Activist investor DOMA Perpetual, which holds a 7.5% stake in Pacira BioSciences, released a letter urging shareholders to vote for its slate of three director nominees at the upcoming annual meeting. The nominees, Christopher Dennis and Oliver Benton 'Ben' Curtis III, argue that the current board has failed to deliver adequate returns and lacks specific expertise in opioid treatment and regulatory litigation relevant to Pacira's business.
Key figures
- Amortization
- 14300000
- Doma shares owned
- 2777794
- Doma ownership pct
- 7.5%
- Q1 2026 adjusted ebitda
- 40200000
- Q1 2026 gaap net income
- 2900000
- Stock based compensation
- 13500000
- Q1 2026 revenue growth yoy
- 5%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.